May 16 (Reuters) - British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon. (Reporting by Anchal Rana in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,766 GBX | +2.11% | -0.45% | +21.81% |
Jun. 01 | Delaware judge lets more than 70,000 Zantac lawsuits go forward | RE |
Jun. 01 | GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,766 GBX | +2.11% | -0.45% | 91.66B | ||
325.1 GBX | +0.12% | +0.65% | 37.78B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.81% | 91.66B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK intends to sell its entire stake in Haleon